

CRISPR Therapeutics reported Phase 1b data for CTX310, showing a 63% triglyceride drop and solid safety in severe hypertriglyceridemia.
You can purchase shares of CRISPR Therapeutics (NASDAQ:CRSP) through any online brokerage.
Other companies in CRISPR Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
CRISPR Therapeutics has a consensus price target of $71.74.
The stock price for CRISPR Therapeutics (NASDAQ: CRSP) is $40.8689 last updated November 19, 2026 at 8:34 AM EST.
There are no upcoming dividends for CRISPR Therapeutics.
CRISPR Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for CRISPR Therapeutics.
CRISPR Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a...